Your browser doesn't support javascript.
loading
Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?
Vourli, Georgia; Noori, Teymur; Pharris, Anastasia; Porter, Kholoud; Axelsson, Maria; Begovac, Josip; Cazein, Francoise; Costagliola, Dominique; Cowan, Susan; Croxford, Sara; d'Arminio Monforte, Antonella; Delpech, Valerie; Díaz, Asunción; Girardi, Enrico; Gunsenheimer-Bartmeyer, Barbara; Hernando, Victoria; Leierer, Gisela; Lot, Florence; Nunez, Olivier; Obel, Niels; Op de Coul, Eline; Paraskeva, Dimitra; Patrinos, Stavros; Reiss, Peter; Schmid, Daniela; Sonnerborg, Anders; Suligoi, Barbara; Supervie, Virginie; van Sighem, Ard; Zangerle, Robert; Touloumi, Giota.
  • Vourli G; Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Noori T; European Centre for Disease Prevention and Control, Solna, Sweden.
  • Pharris A; European Centre for Disease Prevention and Control, Solna, Sweden.
  • Porter K; University College London, London, United Kingdom.
  • Axelsson M; Public Health Agency of Sweden, Solna, Sweden.
  • Begovac J; Department of Infectious Diseases, School of Medicine, University of Zagreb, Zagreb, Croatia.
  • Cazein F; Santé publique France, the French national public health agency, Saint-Maurice, France.
  • Costagliola D; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France.
  • Cowan S; Statens Serum Institut, Copenhagen, Denmark.
  • Croxford S; Public Health England, London, United Kingdom.
  • d'Arminio Monforte A; ASST Santi Paolo e Carlo University Hospital, Milan, Italy.
  • Delpech V; Public Health England, London, United Kingdom.
  • Díaz A; Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain.
  • Girardi E; Istituto Nazionale Malattie Infettive 'L. Spallanzani, Roma, Italy.
  • Gunsenheimer-Bartmeyer B; Robert Koch Institute, Berlin, Germany.
  • Hernando V; Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain.
  • Leierer G; Medical University Innsbruck, Innsbruck, Austria.
  • Lot F; Santé publique France, the French national public health agency, Saint-Maurice, France.
  • Nunez O; Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain.
  • Obel N; Rigshospitalet, Copenhagen University, Copenhagen, Denmark.
  • Op de Coul E; National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
  • Paraskeva D; Hellenic Center for Disease Control and Prevention, Amarousio, Greece.
  • Patrinos S; Hellenic Center for Disease Control and Prevention, Amarousio, Greece.
  • Reiss P; Stichting HIV Monitoring, Amsterdam, The Netherlands.
  • Schmid D; Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • Sonnerborg A; Austrian Agency for Health and Food Safety, Vienna, Austria.
  • Suligoi B; Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
  • Supervie V; National AIDS Unit, Istituto Superiore di Sanita, Rome, Italy.
  • van Sighem A; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France.
  • Zangerle R; Stichting HIV Monitoring, Amsterdam, The Netherlands.
  • Touloumi G; Medical University Innsbruck, Innsbruck, Austria.
Clin Infect Dis ; 71(11): 2905-2916, 2020 12 31.
Article en En | MEDLINE | ID: mdl-32960957
BACKGROUND: High uptake of antiretroviral treatment (ART) is essential to reduce human immunodeficiency virus (HIV) transmission and related mortality; however, gaps in care exist. We aimed to construct the continuum of HIV care (CoC) in 2016 in 11 European Union (EU) countries, overall and by key population and sex. To estimate progress toward the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 target, we compared 2016 to 2013 estimates for the same countries, representing 73% of the population in the region. METHODS: A CoC with the following 4 stages was constructed: number of people living with HIV (PLHIV); proportion of PLHIV diagnosed; proportion of those diagnosed who ever initiated ART; and proportion of those ever treated who achieved viral suppression at their last visit. RESULTS: We estimated that 87% of PLHIV were diagnosed; 92% of those diagnosed had ever initiated ART; and 91% of those ever on ART, or 73% of all PLHIV, were virally suppressed. Corresponding figures for men having sex with men were: 86%, 93%, 93%, 74%; for people who inject drugs: 94%, 88%, 85%, 70%; and for heterosexuals: 86%, 92%, 91%, 72%. The proportion suppressed of all PLHIV ranged from 59% to 86% across countries. CONCLUSIONS: The EU is close to the 90-90-90 target and achieved the UNAIDS target of 73% of all PLHIV virally suppressed, significant progress since 2013 when 60% of all PLHIV were virally suppressed. Strengthening of testing programs and treatment support, along with prevention interventions, are needed to achieve HIV epidemic control.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por VIH Límite: Humans / Male Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por VIH Límite: Humans / Male Idioma: En Año: 2020 Tipo del documento: Article